Overview

Gemini Symbicort pMDI

Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether treatment with Symbicort for 12 weeks will improve lung function and symptoms of adults and adolescents with asthma.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide
Budesonide, Formoterol Fumarate Drug Combination
Formoterol Fumarate